Overview
Abeona Q2 net income of $108.8 mln beats analyst expectations, per LSEG data
Adjusted EPS of $1.71 beats estimates, driven sale of Rare Pediatric Disease priority review voucher (PRVsale)
ZEVASKYN U.S. launch on track and first patient treatment expected in Q3
Says with Abeona transitioning into a commercial organization, some manufacturing and development costs reclassified from R&D expense to inventory or SG&A expenses.
Outlook
Abeona expects first ZEVASKYN treatment in Q3
Company anticipates profitability in 1H 2026
Company plans to scale ZEVASKYN supply to 10 patients/month by mid-2026
Result Drivers
FDA APPROVAL - ZEVASKYN received FDA approval in April 2025 for treating RDEB, marking a key milestone for Abeona
STRONG PATIENT INTEREST - High demand for ZEVASKYN with multiple patients identified and progressing towards treatment, per CEO Vish Seshadri
INSURANCE COVERAGE - Positive insurance coverage established with major national and regional payers, facilitating broad patient access
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 EPS | Beat | $1.71 | -$0.39 (5 Analysts) |
Q2 Net Income | Beat | $108.83 mln | -$19.40 mln (5 Analysts) |
Q2 Income From Operations | Miss | -$22.79 mln | -$19.30 mln (6 Analysts) |
Q2 Cash & Investments | $225.90 mln |
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for Abeona Therapeutics Inc is $20.00, about 67.2% above its August 13 closing price of $6.56
Press Release: ID:nGNX2Lz1Sj
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)